Skip to main content

Breast cancer

Expert commentary

05-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Ribociclib efficacy for visceral metastases

Denise Yardley reports on the outcomes of participants with visceral metastases in the MONALEESA-3 and MONALEESA-7 trials of ribociclib for hormone receptor-positive, HER2-negative breast cancer (8:54).

02-06-2020 | ASCO 2020 | Conference coverage | Video

Expert highlights: Breast cancer at ASCO 2020

Bora Lim rounds up the breast cancer studies that caught her attention at the virtual 2020 ASCO Annual Meeting, including the MONALEESA pooled ctDNA analysis and the BYLieve trial (7:04).

01-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Initial data from CCC19

Jeremy Warner provides a comprehensive overview of the findings from the first 1018 patients with cancer and COVID-19 enrolled in the CCC19 registry (14:40).

01-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The ECOG-ACRIN E2108 trial

Seema Khan puts the results of the phase 3 study of locoregional therapy for de novo stage IV breast cancer in context of the two other studies that addressed the same research question (5:38).

30-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Introducing a phase 1 trial of ladiratuzumab vedotin

Jame Abraham describes the design of a phase 1 trial now investigating the novel LIV-1-targeted antibody–drug ladiratuzumab vedotin in patients with metastatic breast cancer (3:43).

30-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Outcomes of rural breast cancer patients

Suneel Kamath discusses the impact of time to treatment on the survival of rural breast cancer patients (5:31).

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The HER2CLIMB trial

Nancy Lin presents the latest findings from the HER2CLIMB trial, reporting on the intracranial efficacy of tucatinib given alongside trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases (5:12).

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The KEYNOTE-355 trial

Javier Cortes discusses the KEYNOTE-355 trial findings for pembrolizumab plus chemotherapy in patients with recurrent inoperable or metastatic triple-negative breast cancer (5:36).

02-04-2019 | Advanced breast cancer | Editorial | Article

The use of CDK4/6-inhibitors in advanced, hormone-receptor positive breast cancer: why, when and who?

CDK4/6 inhibitors are a valuable addition to the treatment armamentarium for HR-positive, HER2-negative advanced breast cancer, but questions about their use remain. The research team behind the Dutch Sonia study explores some of the most pressing questions.

01-04-2019 | Malignant pleural disease | Video | Article

Researcher comment: CAR T-cell therapy for malignant pleural disease

Prasad Adusumilli outlines the key results of their phase I trial showing promising safety and efficacy of a mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease, and also discusses the next steps (4:09).

19-11-2018 | Head and neck cancers | ESMO 2018 | Video

Experts reflect on their highlights from ESMO 2018

Hisham Mehanna, Ricardo Alvarez and Massimo Christofanilli, and Thomas Seufferlein discuss their ESMO 2018 highlights in head & neck, breast, and gastrointestinal cancer, respectively (7:42).

28-10-2018 | Breast cancer | ESMO 2018 | Video

Tumor-infiltrating lymphocytes show prognostic potential in HER2-positive breast cancer

Maria Vittoria Dieci describes the ShortHER trial’s findings on tumor-infiltrating lymphocytes and their prognostic value in patients undergoing treatment for early HER2-positive breast cancer (6:03).

24-10-2018 | Tamoxifen | ESMO 2018 | Video

Serum analysis sheds light on tamoxifen adherence

Barbara Pistilli discusses the CANTO COMPLETE study of premenopausal breast cancer patient adherence to endocrine therapy (4:31).

24-10-2018 | Breast cancer | ESMO 2018 | Video

Evaluating alpelisib addition to standard of care in SOLAR-1

We speak to Fabrice André about the SOLAR-1 trial and its impact on the care of patients with hormone receptor-positive, HER2-negative advanced breast cancer (5:19).

02-08-2018 | Breast cancer | Editorial | Article

Developing polygenic risk scores for breast cancer

Gareth Evans (University of Manchester, UK) details how genetic advances have allowed the development of relatively cheap and clinically meaningful genetic-based scores for breast cancer risk, further heralding the shift towards precision medicine in breast cancer.

28-06-2018 | Surgery | Editorial | Article

Breast cancer-related lymphedema management: Current state and future directions

Breast cancer-related lymphedema is a debilitating complication of breast cancer surgery. Babak Mehrara (Memorial Sloan Kettering Cancer Center, NY, USA) outlines the current state of lymphedema management and poses some questions for the future.

23-04-2018 | Survivorship | Editorial | Article

Challenges of an aging and increasingly obese breast cancer survivor population: Are we ready?

In an aging population with rising obesity levels, comorbidities and worse overall prognoses for breast cancer patients are a growing concern. Damien Hansra (Cancer Treatment Centers of America, GA, USA) calls for more education and preparation to combat this concerning public health threat.

08-01-2018 | Breast cancer | Editorial | Article

New paradigm: Testing elimination of breast cancer surgery after neoadjuvant systemic therapy

Neoadjuvant chemotherapy can be so effective at shrinking breast tumors in some patients that it has raised the possibility of avoiding surgery altogether. Henry Kuerer (MD Anderson, USA) discusses the exciting recent advances in this area.

Image Credits